ABBV
6/8LiveAbbVie Inc.
NYSE · Healthcare · Drug Manufacturers
$265.79
Blended fair value
$57.51
Well above fair value
Margin of safety
-362.17%
against blended fair value
Expected return
-4.93%
per year, mid case
52-week range
Valuation verdict
Based on your current assumptions
Well above fair value
Fair value $57.51 against a market price of $265.79.
- Margin of safety
- -362.17%
- Expected return
- -4.93%/ yr
Company facts
- Market cap
- $470.45B
- P/E (5yr avg)
- 128.1x
- Day range
- $263.03 – $266.91
- 52-week range
- $190.75 – $267.47
- Volume
- 3.7M
- Sector
- Healthcare
- Industry
- Drug Manufacturers
- Employees
- 50,000
Immunology and aesthetics portfolio managing the loss of Humira exclusivity via Skyrizi and Rinvoq.
Falls short on 2 pillars: p/e ratio, price to free cash flow.
P/E ratio
Fail5yr average P/E below 22.5
Price to free cash flow
Fail5yr average P/FCF below 22.5
Return on invested capital
Pass5yr average ROIC above 9%
Revenue growth
Pass10yr CAGR above 0%
Net income growth
Pass10yr CAGR above 0%
Free cash flow growth
Pass10yr CAGR above 0%
Shares outstanding
PassShare count flat or shrinking over 5 years
Long-term debt to FCF
PassDebt payable from under 5 years of free cash flow
Everything Money is not an investment adviser. The fair-value range on this page is the arithmetic output of assumptions you control, not a forecast or a recommendation. Verify figures against the company's filings before acting. How the method works